Drugs / BAT2506
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05332730 | Aug 2022 → Jun 2023 | psoriatic arthritis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1 | NCT04152759 | Sep 2019 → Dec 2020 | psoriatic arthritis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05046431 | May 2021 → Oct 2023 | psoriatic arthritis | Bio-Thera Solutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT2506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05046431 ↗ |
| Known as | Simponi(EU-licensed) | “Drug: BAT2506 injection Other Names: Simponi(EU-licensed)” NCT04152759 ↗ |
| Route | Subcutaneous | “single subcutaneous administration of 50mg BAT2506 Injection or Simponi® (EU-licensed ).” NCT04152759 ↗ |